Locals alarmed as 'swarms of alien jellyfish' wash up on popular beaches: 'They can find themselves stranded on the shore'
The Mirror reports that "swarms of alien jellyfish" are washing up on the beaches around Torquay in southwest England.
Despite their otherworldly appearance, moon jellyfish are actually native to the coastal waters of the U.K. and are common throughout the world. They are almost entirely water and lack both a brain and a heart. Unlike their venomous cousins, moon jellyfish pose no threat to people.
They are weak swimmers, and as Alexandra Bulgakova of the Marine Conservation Society explained to The Mirror: "Warm waters and abundant food can lead to jellyfish blooms, and if combined with onshore winds, they can find themselves stranded on the shore."
Moon jellyfish are plentiful and occupy a low position in the food chain. They serve as an essential food source for many marine species, including sea birds, fish, sharks, and turtles.
According to the National Marine Sanctuary Foundation, moon jellyfish are an indicator species. When their numbers explode, it's a sign that the health of the ocean's ecosystem is declining, as there are fewer predators to keep their numbers under control.
In the historically temperate U.K., soaring ocean temperatures and vast blooms of jellyfish are a sure sign that something's amiss. In general, warmer waters are conducive to extreme weather events, and British authorities issued heatwave and storm warnings in June 2025, per the BBC.
Keeping moon jellyfish under control and, by extension, improving the overall health of the ocean begins with raising awareness of key environmental issues. Another practical and key step to ensuring less plastic ends up in the ocean is by reducing plastic waste. It's also essential to support local initiatives and back political candidates who prioritize the environment.
Do you think your city does a good job of managing trash and waste?
Yes
Usually
Only sometimes
Not at all
Click your choice to see results and speak your mind.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
an hour ago
- Fox News
Body of Antarctic explorer found after 66 years after his disappearance
The British Antarctic Survey announced that the remains of 25-year-old meteorologist Dennis "Tink" Bell were found 66 years after his disappearance. Although Bell's remains were recovered in January, they were only recently formally identified. "I had long given up on finding my brother. It is just remarkable, astonishing. I can't get over it," David Bell, Dennis' brother, told BBC News. The outlet reported that David was the one to answer the door when the family received a telegraph informing them of the bad news, which he described as a "horrendous moment." David also told the British Antarctic Survey (BAS) that he and his sister, Valerie Kelly, were "shocked and amazed" to hear their brother's remains were found decades after his fatal accident. MISSING FLORIDA MAN WHO WANDERED AWAY AT POPULAR NEW ENGLAND TOURIST DESTINATION FOUND DEAD Samples of David and Valerie's DNA helped Professor Denise Syndercombe Court, a forensic geneticist at King's College London, confirm that the remains were their brother's. The two were "more than one million times" more likely than not to be related, according to BAS. After school, Bell joined the Royal Air Force for National Service and trained as a radio operator before joining the Falkland Islands Dependencies Survey (FIDS) as a meteorologist in 1958. On July 26, 1959, Bell, along with three other men and two dog sleds, set out to climb a glacier leading to an ice plateau, where they planned to conduct survey and geological work. The men separated into pairs with Bell being accompanied by surveyor Jeff Stokes, while meteorologist Ken Gibson was with geologist Colin Barton, according to the BAS. The BAS noted that Bell and Stokes went off approximately 30 minutes before Gibson and Barton. EXPERIENCED CLIMBER DIES AFTER 3,000-FOOT PLUMMET FROM NORTH AMERICA'S HIGHEST PEAK As the dogs grew tired in the deep, soft snow, Bell tried to motivate them by running ahead to urge them on. However, according to the BAS, he did so without his skis. That's when he fell into a crevasse, an accident that led to his death and a decades-long search for his remains. Stokes apparently called down to Bell, who answered. He then lowered a rope and told Bell to tie it to himself. Tragically, Bell tied the rope to his belt and not his body, according to the BAS, citing Anthony Nelson's book, "Of Ice and Men." While the team tried to pull him up to safety, his belt broke, and Bell went back down into the crevasse. This time, however, Bell did not answer. The weather worsened quickly after Bell's fall, and while his colleagues risked their lives to save him, they were unable to do so. Gibson said that after about 12 hours they found the site and realized "there was no way he could have survived," according to the BAS. CLICK HERE TO GET THE FOX NEWS APP "Dennis was one of the many brave FIDS personnel who contributed to the early science and exploration of Antarctica under extraordinarily harsh conditions. Even though he was lost in 1959, his memory lived on among colleagues and in the legacy of polar research. This discovery brings closure to a decades-long mystery and reminds us of the human stories embedded in the history of Antarctic science," BAS Director Professor Dame Jane Francis said in a statement. Bell's remains were transported to the Falkland Islands aboard the BAS Royal Research Ship Sir David Attenborough. They were then handed over to His Majesty's Coroner for the British Antarctic Territory, Malcolm Simmons, who accompanied them from Stanley in the Falkland Islands to London.
Medscape
6 hours ago
- Medscape
Growth Charts for Twins Improve Perinatal Risk Prediction
TOPLINE: New customised growth charts for twins (GROW-T), adjusted for maternal characteristics, more accurately predicted a small-for-gestational age (SGA)-associated risk for adverse perinatal outcomes than charts for singletons (GROW-S). METHODOLOGY: Researchers developed customised growth charts for twin pregnancies and compared them with singleton charts to evaluate their ability to identify SGA twins who are at an increased risk for adverse perinatal outcomes. They evaluated 8457 twin pregnancies (16,914 foetuses) from 127 NHS hospitals in the UK from January 2015 to February 2025, representing approximately two thirds of all NHS units. A mixed-effects linear regression analysis was performed to determine pregnancy-specific optimal weights at 37 weeks. Researchers compared GROW-T with GROW-S by calculating rates of the SGA-associated risk for stillbirth and adverse neonatal outcomes, such as the need for resuscitation, an Apgar score < 7 at 5 minutes, admission to the NICU, or neonatal death, using generalised estimating equations. TAKEAWAY: At 37 weeks, the average optimal weight of a twin was 389 g less than that of an equivalent singleton foetus. By pregnancy, 24.6% vs 64.9% of twins were classified as those with SGA (< 10th centile) according to GROW-T vs GROW-S; when analysed by individual foetuses, 13.8% vs 44.4% of twins were classified as those with SGA according to GROW-T vs GROW-S. Twins designated as SGA on the basis of GROW-T (odds ratio [OR], 7.2; 95% CI, 4.8-10.8) had a higher risk for stillbirth than those designated as SGA on the basis of GROW-S (OR, 2.8; 95% CI, 1.9-4.1). Twins classified as those with SGA on the basis of GROW-T had an increased need for resuscitation (OR, 1.3; 95% CI, 1.1-1.7), a lower Apgar score (< 7) at 5 minutes (OR, 1.8; 95% CI, 1.2-2.6), higher NICU admissions (OR, 1.3; 95% CI, 1.0-1.6), and an increased risk for neonatal death (OR, 5.4; 95% CI, 1.3-23.5). IN PRACTICE: "Our results add to the increasing evidence for adoption of twin specific charts," the authors wrote. "While adoption of twin specific charts is timely, implementation ought to be accompanied by evaluation in practice to monitor safety in different health service environments," they added. SOURCE: This study was led by Jason Gardosi, MD, Perinatal Institute, Birmingham, England, and was published online on August 01, 2025, in the American Journal of Obstetrics & Gynecology. LIMITATIONS: Ultrasound estimates of foetal weight in twins can be systematically overestimated, potentially affecting the accuracy of growth assessments. Chorionicity was not reported in the study cohort; however, the difference between growth curves of monochorionic and dichorionic twins was considered too small to be clinically relevant. DISCLOSURES: No funding information was provided for the study. All authors reported being employees of the Perinatal Institute, Birmingham, England. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
7 hours ago
- Yahoo
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected in all three indications this year with first-in-class potential in NT2 and IH ORX142 Phase 1 clinical trial for the treatment of select neurological and neurodegenerative disorders underway with data in acutely sleep-deprived healthy volunteers expected this year ORX489 in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results and business highlights for the second quarter ended June 30, 2025. 'As clinical validation of the orexin agonist class continues to grow, we believe Centessa is well positioned with a novel potential best-in-class OX2R agonist pipeline aimed at redefining the standard of care. This includes not only restoring normal wakefulness to meet the real-world needs of individuals with sleep-wake disorders, but also potentially addressing comorbidities such as excessive daytime sleepiness, impaired attention, cognitive deficits and fatigue across a range of neurological, neurodegenerative and neuropsychiatric conditions where there is unmet need,' said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. Dr. Saha continued, 'ORX750, our most advanced OX2R agonist drug candidate, is progressing in an adaptive Phase 2a study that incorporates real-time drug development strategies aimed at optimizing dosing and best positioning ORX750 for planned registrational studies. This innovative approach continues to build our confidence in ORX750's potential to be a best-in-class OX2R agonist for the treatment of NT1, NT2 and IH, and potentially the first OX2R agonist to treat NT2 and IH. Our top priority remains the successful execution of the Phase 2a study, and we look forward to sharing data for ORX750 in all three indications this year.' 'In parallel, we recently initiated clinical development of ORX142, our second OX2R agonist drug candidate, with data in acutely sleep-deprived healthy volunteers also expected this year. With two programs advancing toward key clinical milestones and a broad pipeline of potentially transformative orexin therapies, we believe Centessa is positioned to become a long-term leader in the orexin space,' concluded Dr. Saha. Recent Highlights Following clearance of the Investigational New Drug application (IND) from the U.S. Food and Drug Administration (FDA) in June 2025, the Company initiated a Phase 1 first-in-human clinical trial of ORX142, with data in acutely sleep-deprived healthy volunteers expected this year. In April 2025, additional data from the Phase 1 study of ORX750 were presented in a poster session at the American Academy of Neurology (AAN) Annual Meeting. Along with previously disclosed Phase 1 data, the poster highlighted time-course curves for both the Maintenance of Wakefulness Test (MWT) and the Karolinska Sleepiness Scale (KSS) from the 5.0 mg dose cohort. At this dose, sustained effects were observed across the full 8-hour post-dose observation period, with mean sleep latency exceeding 30 minutes on the MWT and improvements in KSS scores compared to placebo. An abstract highlighting the adaptive design of the Company's Phase 2a CRYSTAL-1 study for ORX750, including an open-label long-term extension (LTE), has been accepted as a poster presentation at the World Sleep 2025 Congress being held on September 5–10, 2025, in Singapore. The abstract, Development of a Novel, Oral Orexin Receptor 2 Agonist, ORX750 for Treatment of Patients with Narcolepsy (type 1 and 2) and Idiopathic Hypersomnia, is available on the conference website. A copy of the poster will be available on the Centessa website at at the time of the poster presentation. OX2R Agonist Pipeline and Anticipated Upcoming Milestones ORX750: The Phase 2a CRYSTAL-1 study is ongoing with data in NT1, NT2 and IH expected in 2025. ORX142: The Phase 1 first-in-human study of ORX142 is ongoing with data in acutely sleep-deprived healthy volunteers expected in 2025. ORX489: Currently in IND-enabling studies. Second Quarter 2025 Financial Results Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments totaled $404.1 million as of June 30, 2025. The Company expects its cash, cash equivalents and investments as of June 30, 2025 will fund operations into mid-2027. Research & Development (R&D) Expenses: R&D expenses were $42.7 million for the second quarter ended June 30, 2025, compared to $32.8 million for the second quarter ended June 30, 2024. General & Administrative (G&A) Expenses: G&A expenses were $11.9 million for the second quarter ended June 30, 2025, compared to $11.2 million for the second quarter ended June 30, 2024. Net Loss: Net loss was $50.3 million for the second quarter ended June 30, 2025, compared to $43.8 million for the second quarter ended June 30, 2024. About Centessa's Orexin Receptor 2 (OX2R) Agonist Program Orexin is a neuropeptide that regulates the sleep-wake cycle, leading to arousal and promoting wakefulness. Targeting the orexin pathway with novel orexin receptor 2 (OX2R) agonists represents a potential promising approach to address excessive daytime sleepiness (EDS), impaired attention, cognitive deficits and fatigue associated with a broad range of neurological, neurodegenerative and neuropsychiatric disorders. Centessa is developing a pipeline of potential best-in-class OX2R agonists, including ORX750 for the treatment of sleep-wake disorders including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), ORX142 for the treatment of select neurological and neurodegenerative disorders, and ORX489 for the treatment of neuropsychiatric disorders. ORX750 is being evaluated in the Phase 2a CRYSTAL-1 study. For more information, visit ORX750, ORX142 and ORX489 are investigational candidates and have not been approved by the FDA or any other regulatory authority. About Centessa Pharmaceuticals Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of EDS, impaired attention, cognitive deficits and fatigue across neurological, neurodegenerative and neuropsychiatric disorders. For more information, visit which does not form part of this release. Forward Looking Statements This press release contains forward-looking statements. These statements may be identified by words such as 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'objective,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'continue,' 'ongoing,' 'aim,' 'seek,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including statements related to the Company's ability to discover and develop transformational medicines for patients; its expectations for executing on the Company's pipeline; its expectations on its anticipated cash runway; the timing of commencement of new studies or clinical trials or clinical and preclinical data related to ORX750, ORX142, ORX489 and other OX2R agonist molecules; its ability to identify, screen, recruit and maintain a sufficient number of or any subjects in its existing and anticipated studies or clinical trials of ORX750, ORX142, ORX489 and other OX2R agonist molecules; its expectations on executing its research and clinical development plans and the timing thereof; its expectations as to the potential results and impact of each of its clinical programs and trials; the Company's ability to differentiate ORX750, ORX142, ORX489 and other OX2R agonist molecules from other treatment options, including those being developed by competitors; the development, design and therapeutic potential of ORX750, ORX142, ORX489 and other OX2R agonist molecules, including the potential for ORX750 to be a best-in-class OX2R agonist for the treatment of NT1, NT2 and IH, and potentially the first OX2R agonist to treat NT2 and IH; and regulatory matters, including the timing and likelihood of success of obtaining regulatory clearance or authorizations to initiate or continue clinical trials. Any forward-looking statements in this press release are based on our current expectations, estimates, assumptions and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the safety and tolerability profile of our product candidates; our ability to identify, screen and recruit a sufficient number of or any subjects in our existing and anticipated new studies or clinical trials of ORX750, ORX142, ORX489 or within anticipated timelines; our expectations relating to the clinical trials of ORX750 and ORX142, including the predicted timing of enrollment, the predicted efficacious doses of ORX750 and ORX142 and our ability to successfully conduct our clinical development of ORX750 and ORX142, our ability to protect and maintain our intellectual property position; business (including commercial viability), regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company; risks inherent in developing product candidates and technologies; future results from our ongoing and planned clinical trials; our ability to obtain adequate financing, including through our financing facility with Oxford Finance, to fund our planned clinical trials and other expenses; trends in the industry; the legal and regulatory framework for the industry, including the receipt and maintenance of clearances to conduct or continue clinical testing; our operating costs and use of cash, including cash runway, cost of development activities and conducting clinical trials, future expenditures risks; the risk that any one or more of our product candidates will not be successfully developed and/or commercialized; the risk that the historical results of preclinical studies or clinical studies will not be predictive of future results in ongoing or future studies; economic risks to the United States and United Kingdom banking systems; and geo-political risks such as the Russia-Ukraine war, the Middle East conflicts or trade wars and impact of the imposition of tariffs. These and other risks concerning our programs and operations are described in additional detail in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and our other reports, which are on file with the U.S. Securities and Exchange Commission (SEC). We explicitly disclaim any obligation to update any forward-looking statements except to the extent required by law. Contact: Kristen K. Sheppard, Esq. SVP of Investor Relations investors@ Centessa Pharmaceuticals plcConsolidated Statements of Operations and Comprehensive Loss(unaudited)(amounts in thousands except share and per share data) Three Months EndedJune 30, 2025 Three Months EndedJune 30, 2024 Six Months EndedJune 30, 2025 Six Months EndedJune 30, 2024 License and other revenue $ — $ — $ 15,000 $ — Operating expenses: Research and development 42,741 32,815 76,184 55,467 General and administrative 11,912 11,165 24,246 24,603 Loss from operations (54,653 ) (43,980 ) (85,430 ) (80,070 ) Interest and investment income 4,380 3,240 12,270 5,831 Interest expense (2,884 ) (2,525 ) (5,761 ) (5,054 ) Other non-operating income (expense), net 3,592 154 4,618 (1,383 ) Loss before income taxes (49,565 ) (43,111 ) (74,303 ) (80,676 ) Income tax expense 778 705 2,175 1,186 Net loss (50,343 ) (43,816 ) (76,478 ) (81,862 ) Other comprehensive (loss) income: Foreign currency translation adjustment (479 ) (61 ) 164 (86 ) Unrealized (loss) gain on available for sale marketable securities, net of reclassification adjustment and tax (5 ) 33 (2,786 ) 188 Other comprehensive (loss) income (484 ) (28 ) (2,622 ) 102 Total comprehensive loss $ (50,827 ) $ (43,844 ) $ (79,100 ) $ (81,760 ) Net loss per ordinary share - basic and diluted $ (0.38 ) $ (0.40 ) $ (0.57 ) $ (0.78 ) Weighted average ordinary shares outstanding - basic and diluted 133,677,405 109,489,184 133,354,373 104,688,452 Centessa Pharmaceuticals plcCondensed Consolidated Balance Sheets(unaudited)(amounts in thousands) June 30, 2025 December 31, 2024 Total assets: Cash and cash equivalents $ 44,242 $ 383,221 Investments in marketable securities 359,888 98,956 Other assets 87,997 94,621 Total assets $ 492,127 $ 576,798 Total liabilities Other liabilities $ 37,663 $ 66,313 Long term debt 109,545 108,940 Total liabilities 147,208 175,253 Total shareholders' equity 344,919 401,545 Total liabilities and shareholders' equity $ 492,127 $ 576,798 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
